Pasithea Therapeutics Cor... (KTTAW)
Pasithea Therapeutics Statistics
Share Statistics
Pasithea Therapeutics has 70.33M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 70.33M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 62.02% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 4.75K |
| FTD / Avg. Volume | 32.27% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is null. Pasithea Therapeutics's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.4 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pasithea Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of undefined.
| Current Ratio | 6.34 |
| Quick Ratio | 6.35 |
| Debt / Equity | undefined |
| Debt / EBITDA | - |
| Debt / FCF | - |
| Interest Coverage | undefined |
Financial Efficiency
Return on Equity is -0.68% and Return on Invested Capital is -68.05%.
| Return on Equity | -0.68% |
| Return on Assets | -0.61% |
| Return on Invested Capital | -68.05% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | -16.01 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 69.49% in the last 52 weeks. The beta is 0.82, so Pasithea Therapeutics's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | 69.49% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 48.83 |
| Average Volume (20 Days) | 14.73K |
Income Statement
| Revenue | n/a |
| Gross Profit | -648.45K |
| Operating Income | -15.98M |
| Net Income | -15.96M |
| EBITDA | -15.33M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -12.65 |
Balance Sheet
The company has 16.33M in cash and 81.68K in debt, giving a net cash position of 16.25M.
| Cash & Cash Equivalents | 16.33M |
| Total Debt | 81.68K |
| Net Cash | 16.25M |
| Retained Earnings | -35.32M |
| Total Assets | 18.64M |
| Working Capital | 9.12B |
Cash Flow
In the last 12 months, operating cash flow was -13.43M and capital expenditures -34.3K, giving a free cash flow of -12.85M.
| Operating Cash Flow | -13.43M |
| Capital Expenditures | -34.3K |
| Free Cash Flow | -12.85M |
| FCF Per Share | -10.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KTTAW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -42166.67% |
| FCF Yield | -709.47% |
Analyst Forecast
Currently there are no analyst rating for KTTAW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 580.85 |
| Piotroski F-Score | 3 |